A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin; Tegobuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 10 Oct 2011 According to the Clinical Trials Database record, status changed from recruiting to completed.
    • 08 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top